Archives
Foxp1 Suppresses Notch-Mediated EndMT to Reduce Valve Calcif
2026-06-20
Foxp1 Suppresses Notch-Mediated EndMT to Reduce Valve Calcification in CKD
Study Background and Research Question
Valvular calcification (VC) is a common and serious complication in patients with chronic kidney disease (CKD), closely linked to increased cardiovascular events and all-cause mortality. As kidney function declines, serum parathyroid hormone (PTH) levels rise, which accelerates the progression of VC and contributes to cardiac dysfunction. Previous studies demonstrated that PTH promotes VC by inducing endothelial-to-mesenchymal transition (EndMT) in valve endothelial cells (VECs), thereby driving the pathological transformation of these cells into osteogenic, calcifying phenotypes. However, the molecular regulators that restrain this process, particularly in the context of CKD, remain poorly defined. The present study by Wang et al. (see summary) addresses a critical question: Does overexpression of Forkhead box P1 (Foxp1) in endothelial cells inhibit PTH-induced EndMT and thereby attenuate valvular calcification in CKD, and what are the underlying pathways mediating this effect?Key Innovation from the Reference Study
The central innovation is the identification of Foxp1 as a molecular brake on Notch pathway activation, which in turn suppresses EndMT and the downstream calcific remodeling of cardiac valves in CKD models. By demonstrating that endothelial-specific overexpression of Foxp1 (Foxp1EC-OE) leads to reduced calcification and improved endothelial integrity, the study offers mechanistic clarity on how the balance of PTH signaling and Foxp1-regulated transcription controls pathological tissue transformation in the cardiovascular system under CKD stress. Importantly, the study pinpoints the Jagged-1/Notch axis as a direct target of Foxp1-mediated repression, providing a concrete molecular node for potential therapeutic targeting.Methods and Experimental Design Insights
To dissect the molecular pathways linking PTH signaling, EndMT, and VC, the authors employed both genetic and disease modeling approaches:- Generation of endothelial-specific Foxp1 overexpressing mice (Foxp1EC-OE) by crossing Foxp1 knock-in mice with Cdh5-Cre (ERT2) drivers, enabling cell-type-specific gene modulation.
- Induction of CKD and associated VC in murine models, with confirmation of hydroxyapatite deposition in cardiac valves, reflecting clinical pathology.
- In vitro assays using valve endothelial cells (VECs) and valvular interstitial cells (VICs) were performed to analyze EndMT progression, migration, and osteogenic transition under different experimental conditions, including PTH exposure and manipulation of Foxp1 expression.
- Chromatin immunoprecipitation (ChIP) and quantitative PCR (ChIP-qPCR) were used to demonstrate Foxp1 binding at the Jagged-1 promoter, providing direct evidence of transcriptional repression.
- Markers of EndMT (e.g., VE-cadherin, ZO-1), osteogenic transition, and inflammatory responses (HMGB1-driven macrophage infiltration) were analyzed by immunostaining and gene expression profiling.
Protocol Parameters
- CKD induction in mice: Standardized nephrectomy or adenine-rich diet protocols were used for chronic kidney disease modeling, with protocol durations typically ranging from 4 to 8 weeks.
- PTH stimulation: Parathyroid hormone (1-34) (human) administered subcutaneously at 10 or 40 μg/kg/day for up to 4 weeks, as reported in related studies (product information).
- EndMT and osteogenic marker assessment: Immunostaining for VE-cadherin, ZO-1 (endothelial markers), and osteogenic proteins (e.g., Runx2, osteocalcin) was performed at endpoint.
- ChIP-qPCR: Foxp1 binding to the Jagged-1 promoter quantified using established antibody-based enrichment protocols.
Core Findings and Why They Matter
The study establishes several mechanistically significant findings:- Foxp1 overexpression in endothelium reduces VC: Foxp1EC-OE mice exhibited markedly less valvular calcification compared to CKD controls, as evidenced by histological analysis and calcium quantification.
- Suppression of EndMT and Notch signaling: Foxp1 overexpression inhibited the loss of endothelial markers in VECs and reduced acquisition of mesenchymal/osteogenic traits, correlating with diminished Notch pathway activation. Chromatin analyses confirmed direct repression of the Jagged-1 promoter by Foxp1.
- Mitigation of inflammatory infiltration and osteogenic transition: Foxp1 restored endothelial barrier integrity and reduced HMGB1-driven macrophage infiltration, decreasing the secretion of TGF-β1 and limiting VICs’ osteogenic transformation.
- Pathway integration: The data support a model in which PTH-induced elevation in Notch signaling drives EndMT and valve calcification, while Foxp1 acts upstream to restrain this process.
Comparison with Existing Internal Articles
Recent internal resources reinforce the reference study’s findings and extend practical insight for translational researchers:- The article "Precision in Translational Discovery: Leveraging Parathyroid Hormone (1-34) (human)" discusses how the PTH (1-34) peptide fragment enables detailed study of PTH/PTHrP receptor signaling and calcium homeostasis in bone and kidney research. This complements the current study’s focus on PTH-driven EndMT and VC by providing experimental context for peptide-driven pathway modeling.
- The protocol-driven resource "Applied Protocols with Parathyroid hormone (1-34) (human) in Bone and Kidney Models" offers workflow enhancements for bone metabolism and CKD-driven calcification studies, which are directly relevant to the methodologies adopted in the Foxp1-VC investigation.
- For atomic-level insight into peptide handling and signaling, "Parathyroid hormone (1-34) (human): Atomic Insights and Best Practices" provides guidance on solubility, receptor specificity, and experimental use, further supporting reproducibility in similar research workflows.
Limitations and Transferability
While the study offers compelling evidence for Foxp1 as a Notch pathway repressor and EndMT inhibitor in CKD-related VC, several limitations should be noted:- Species and model specificity: Most findings are based on murine models, and while these recapitulate key aspects of human VC, translational differences may exist in regulatory pathway sensitivity and tissue remodeling dynamics.
- Context of PTH stimulation: Although the study leverages the established role of PTH in CKD-VC, the precise dosing and duration for mimicking chronic human disease remain to be optimized for maximal translational relevance. Related internal articles (protocols) recommend careful control of peptide concentration and administration schedule to model disease progression.
- Pathway complexity: The Notch/Jagged-1 axis is but one of several intersecting networks implicated in EndMT and calcification. Additional factors (e.g., Wnt, BMP, oxidative stress) may modulate the effectiveness of Foxp1-based interventions, which were outside the scope of the current study.
- Clinical translation: While Foxp1 and Notch pathway modulation show promise in preclinical models, safety, specificity, and delivery challenges must be addressed before considering therapeutic applications in humans.